rhgad65
Gene therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Dec 31, 2021 (NCT05018585)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Glutamate decarboxylase 65 kDa isoformSupplementation
GAD2 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05018585 | Phase 3 | Dec 31, 2021 | Diamyd, Linkoping University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Diamyd | For profit | 1 | 1 | 1 | 2021 |
| Linkoping University | Academic/Hospital | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1